Biotest AG (ETR:BIO) received a €19.00 ($22.35) target price from equities researchers at equinet AG in a note issued to investors on Friday. The brokerage presently has a “neutral” rating on the stock.

Several other equities research analysts have also weighed in on BIO. Kepler Capital Markets set a €15.60 ($18.35) target price on Biotest AG and gave the stock a “neutral” rating in a research report on Saturday, May 20th. Hauck & Aufhaeuser set a €19.00 ($22.35) target price on Biotest AG and gave the stock a “neutral” rating in a research report on Saturday, May 20th.

Biotest AG (BIO) opened at 27.67 on Friday. The stock’s market cap is €1.09 billion. The firm has a 50-day moving average price of €27.42 and a 200 day moving average price of €24.44. Biotest AG has a 1-year low of €15.02 and a 1-year high of €28.48.

ILLEGAL ACTIVITY NOTICE: “Biotest AG (ETR:BIO) Given a €19.00 Price Target at equinet AG” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.dailypolitical.com/2017/08/11/biotest-ag-etrbio-given-a-19-00-price-target-at-equinet-ag.html.

Biotest AG Company Profile

Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology and intensive care medicine. Biotest AG develops, manufactures and markets immunoglobulin, coagulation factors and albumins based on human blood plasma.

Receive News & Ratings for Biotest AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biotest AG and related companies with MarketBeat.com's FREE daily email newsletter.